Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort

Wanlong Wu,1 Suzana Jordan,1 Nicole Graf,2 Janethe de Oliveira Pena,3 John Curram,4 Yannick Allanore,5 Marco Matucci-Cerinic,6 Janet E Pope,7 Christopher P Denton,8 Dinesh Khanna,9 Oliver Distler,1 EUSTAR Collaborators

ABSTRACT

Objectives To determine whether progressive skin fibrosis is associated with visceral organ progression and mortality during follow-up in patients with diffuse cutaneous systemic sclerosis (dcSSc).

Methods We evaluated patients from the European Scleroderma Trials and Research database with dcSSc, baseline modified Rodnan skin score (mRSS) ≥7, valid mRSS at 12±3 months after baseline and ≥1 annual follow-up visit. Progressive skin fibrosis was defined as an increase in mRSS ≥5 and ≥25% from baseline to 12±3 months. Outcomes were pulmonary, cardiovascular and renal progression, and all-cause death. Associations between skin progression and outcomes were evaluated by Kaplan-Meier survival analysis and multivariable Cox regression.

Results Of 1021 included patients, 78 (7.6%) had progressive skin fibrosis (skin progressors). Median follow-up was 3.4 years. Survival analyses indicated that skin progressors had a significantly higher probability of FVC decline ≥10% (53.6% vs 34.4%; p<0.001) and all-cause death (15.4% vs 7.3%; p=0.003) than non-progressors. These significant associations were also found in subgroup analyses of patients with either low baseline mRSS (≤22/51) or short disease duration (≤15 months). In multivariable analyses, skin progression within 1 year was independently associated with FVC decline ≥10% (HR 1.79, 95% CI 1.20 to 2.65) and all-cause death (HR 2.58, 95% CI 1.31 to 5.09).

Conclusions Progressive skin fibrosis within 1 year is associated with decline in lung function and worse survival in dcSSc during follow-up. These results confirm mRSS as a surrogate marker in dcSSc, which will be helpful for cohort enrichment in future trials and risk stratification in clinical practice.

INTRODUCTION

Systemic sclerosis (SSc) is a highly heterogeneous connective tissue disease with major morbidity and mortality caused by the development of visceral organ complications. These include interstitial lung fibrosis, pulmonary arterial hypertension, scleroderma renal crisis (SRC), and cardiac and gastrointestinal involvement. A major challenge for physicians is to identify patients at high risk of future complications before irreversible visceral involvement occurs. With several new disease-modifying agents in late-stage development, improved identification of at-risk patients will become even more important to inform early treatment intervention. In addition, it will provide important information for cohort enrichment in future clinical trials.

Skin fibrosis is a hallmark of SSc. The modified Rodnan skin score (mRSS) rates skin thickness from 0 (normal) to 3 (severe) at 17 body surface areas in a standardised manner. The mRSS is feasible, reliable and sensitive to change, and is now commonly used in routine practice and clinical trials.

Using the European Scleroderma Trials and Research (EUSTAR) database, we previously identified short disease duration (≤15 months) and low baseline mRSS (≤22/51) as independent predictors of progressive skin fibrosis (defined as >5 units and ≥25% increment in mRSS at 1-year follow-up) in patients with diffuse cutaneous SSc (dcSSc). While...
this evidence-based strategy of including patients with dcSSc with low baseline mRSS can improve cohort enrichment for progressive skin fibrosis in clinical trials,10 it might lead to recruitment of patients with overall milder disease. Previous studies have suggested that mRSS may be a potential surrogate marker for disease severity and mortality, but these data were derived from older studies and/or selected patients from clinical trials (D-penicillamine).11 12 Therefore, new data are required to clarify whether worsening skin fibrosis is an appropriate surrogate marker for new onset or deterioration of visceral organ disease and overall survival in dcSSc.

In a previous single-centre retrospective study of patients with early dcSSc, patients with high baseline mRSS and no subsequent skin improvement within 2 years had significantly higher mortality than those with skin improvement irrespective of baseline mRSS, while the results for internal organ-based endpoints were contradictory.13 The study thus suggested the prognostic value of the evolution of skin fibrosis, in addition to absolute skin scores, in predicting disease outcome for patients with dcSSc. We herein hypothesise that progression of skin fibrosis within 1 year might be associated with progression of visceral organ disease and mortality in dcSSc during follow-up. The aim of the current study was to test this hypothesis in the large, systematic, longitudinal, real-life EUSTAR registry.

METHODS

More details on methods can be found in the online supplement.

Patients and study design

For this observational study, data from patients’ visits from 1 January 2009 to 31 August 2017 were exported from the EUSTAR database. The structure of the EUSTAR database and minimum essential dataset have been described previously.14 15

Inclusion criteria for the study were classification of SSc (1980 American College of Rheumatology criteria16), diffuse cutaneous involvement as described by LeRoy et al.,17 at least one available annual follow-up visit, mRSS ≥7 (the minimal value for subclassification as dcSSc) at the first available visit (baseline) and valid mRSS data at 12±3 months after baseline.

Definition of ‘progressor’ patients

Patients with progression of skin fibrosis (skin progressors) were defined as those with an increase in mRSS >5 units and by ≥25% from baseline to 12±3 months. This mRSS threshold is considered as the minimally clinical important difference.18 The 1-year period to define skin progression was chosen as it is considered sufficient to capture significant changes in mRSS and is thus frequently used in clinical trials in skin fibrosis.19

Follow-up and outcome measures

Follow-up was defined as the time between the first available visit (baseline) and the last available annual follow-up for each patient. All outcome events were accounted during this period. Outcome measures reflecting visceral organ progression were defined by consensus of an expert group (YA, MM-C, JEP, CPD, DK and OD) using the nominal group technique. Organ progression was defined as occurrence of one of the following events during follow-up: (1) relative decrease in FVC ≥10% from baseline; (2) reduction of left ventricular ejection fraction (LVEF) to <45%, or relative decrease of LVEF >10% for patients with baseline LVEF <45%, assessed by echocardiography; (3) new-onset pulmonary hypertension (PH) as globally judged on echocardiography by the treating physician; (4) new-onset SRC; (5) all-cause death.20–23 Overall disease progression was defined as the presence of any of the above outcomes. In addition, an exploratory analysis in which lung progression was defined as a relative decrease from baseline to follow-up in FVC ≥10%, or 5%–9% combined with diffusing capacity for carbon monoxide (DLCO) ≥15% (instead of definition 1), was performed based on recently proposed criteria.24

Statistical analysis

Baseline characteristics were described as mean (SD) for continuous variables and number (frequency) for categorical variables. Baseline variables were compared between skin progressors and non-progressors by univariate analysis followed by Bonferroni correction. Chi-squared tests or Fisher’s exact tests were used for categorical variables, and independent sample t-tests were used for continuous variables.

Kaplan-Meier curves and log-rank tests were performed to compare outcomes between skin progressors and non-progressors for up to 8 years of follow-up. Only the first event was considered. Patients with PH or SRC at baseline were excluded from analyses of PH and SRC outcomes, as these patients could not show any new event of these types. Kaplan-Meier analyses were also conducted in subgroups stratifying patients by either baseline mRSS (≤22/51 vs >22/51 units) or disease duration (≤15 vs >15 months). Multivariable Cox regression analyses were performed to examine independent associations between skin progression and both FVC decline ≥10% and all-cause death. Confounding variables for multivariable Cox regression models were selected using the nominal group technique. Spearman rho analyses were conducted to measure the correlation between variables before multivariable regression. Multiple imputation with 10 imputed datasets was used before regression analysis to handle missing values.

Significance was defined as p value <0.05. Statistical analyses were performed by the biostatistician (NG) using R programming language (V3.3.3), packages ‘survival’ and ‘mice’.21–27

RESULTS

Baseline characteristics

In total, 1021 patients were included for analysis, of whom 78 (7.6%) had progression of skin fibrosis at 1-year follow-up. Demographic and clinical characteristics are summarised in table 1. Mean age was 52.0 years, mean disease duration was 7.7 years and mean±SD mRSS was 16.9±7.7 at baseline. Median follow-up was 3.4 years. By using Bonferroni correction, the modified critical p value (α) was determined as 0.0013. Skin progressors had a significantly shorter disease duration at baseline than non-progressors, confirming previous results.9 All other baseline characteristics were comparable between groups (table 1).

Associations between skin progression and visceral organ progression

Lung progression

In total, 282 of 788 patients (35.8%) met the FVC definition of lung progression (relative decrease in FVC ≥10%) during a median follow-up of 3.7 years (IQR 1.8–6.2 years). In the overall cohort, 403 of 670 patients (60.1%) had lung fibrosis on CT scan at baseline. The mean±SD FVC at baseline was 86.9%±20.5%, with 164 patients (20.8%) having a baseline FVC <70%. There were 30 (53.6%) and 232 (34.4%) events in the skin progressor and non-progressor groups, respectively. The probability of FVC decline was significantly higher for skin progressors than
## Systemic sclerosis

### Table 1  Baseline demographic and clinical characteristics of skin progressors and non-progressors

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Missing cases, n (%)</th>
<th>Whole cohort (n=1021)</th>
<th>Progressors (n=78)</th>
<th>Non-progressors (n=943)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years (mean±SD)</td>
<td>0 (0) 52.0±13.7</td>
<td>51.7±12.9</td>
<td>52.0±13.7</td>
<td>0.869</td>
<td></td>
</tr>
<tr>
<td>Male sex</td>
<td>0 (0) 248 (24.3)</td>
<td>30 (38.5)</td>
<td>218 (23.1)</td>
<td>0.004</td>
<td></td>
</tr>
<tr>
<td>Disease duration* years (mean±SD)</td>
<td>78 (7.6) 7.7±7.5</td>
<td>5.3±6.2</td>
<td>7.9±7.5</td>
<td>0.006</td>
<td></td>
</tr>
<tr>
<td>≤15 months</td>
<td>78 (7.6) 126 (13.4)</td>
<td>19 (27.9)</td>
<td>107 (12.2)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>≥36 months</td>
<td>78 (7.6) 298 (31.6)</td>
<td>36 (52.9)</td>
<td>262 (29.9)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td><strong>Vascular</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raynaud's phenomenon</td>
<td>2 (0.2) 997 (97.8)</td>
<td>74 (94.9)</td>
<td>923 (98.1)</td>
<td>0.141</td>
<td></td>
</tr>
<tr>
<td>Digital ulcers</td>
<td>11 (1.1) 384 (38.0)</td>
<td>30 (38.5)</td>
<td>354 (38.0)</td>
<td>1.000</td>
<td></td>
</tr>
<tr>
<td>Active digital ulcers</td>
<td>25 (2.4) 199 (20.0)</td>
<td>17 (22.1)</td>
<td>238 (25.4)</td>
<td>0.614</td>
<td></td>
</tr>
<tr>
<td><strong>Skin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mRSS, unit (mean±SD)</td>
<td>0 (0) 16.9±7.7</td>
<td>14.8±6.2</td>
<td>17.1±7.7</td>
<td>0.010</td>
<td></td>
</tr>
<tr>
<td>mRSS ≤22/51</td>
<td>0 (0) 819 (80.2)</td>
<td>67 (85.9)</td>
<td>752 (79.7)</td>
<td>0.245</td>
<td></td>
</tr>
<tr>
<td><strong>Musculoskeletal</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tendon friction rubs</td>
<td>11 (1.1) 156 (15.4)</td>
<td>10 (13.0)</td>
<td>146 (15.6)</td>
<td>0.648</td>
<td></td>
</tr>
<tr>
<td>Joint synovitis</td>
<td>6 (0.6) 180 (17.7)</td>
<td>16 (20.5)</td>
<td>164 (17.5)</td>
<td>0.607</td>
<td></td>
</tr>
<tr>
<td>Joint contractures</td>
<td>7 (0.7) 505 (49.8)</td>
<td>42 (53.8)</td>
<td>463 (50.2)</td>
<td>0.532</td>
<td></td>
</tr>
<tr>
<td>Muscle weakness</td>
<td>6 (0.6) 255 (25.1)</td>
<td>17 (21.1)</td>
<td>238 (25.4)</td>
<td>0.925</td>
<td></td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oesophageal symptoms</td>
<td>1 (0.1) 687 (67.4)</td>
<td>51 (65.4)</td>
<td>636 (67.5)</td>
<td>0.795</td>
<td></td>
</tr>
<tr>
<td>Stomach symptoms</td>
<td>2 (0.2) 300 (29.4)</td>
<td>34 (42.4)</td>
<td>266 (28.7)</td>
<td>0.361</td>
<td></td>
</tr>
<tr>
<td>Intestinal symptoms</td>
<td>3 (0.3) 281 (27.6)</td>
<td>21 (26.9)</td>
<td>260 (27.7)</td>
<td>0.994</td>
<td></td>
</tr>
<tr>
<td><strong>Cardiopulmonary</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspnoea (NYHA)</td>
<td>84 (8.2) 520 (51.5)</td>
<td>34 (41.5)</td>
<td>486 (51.5)</td>
<td>0.186</td>
<td></td>
</tr>
<tr>
<td>Stage 1</td>
<td>11 (1.1) 156 (15.4)</td>
<td>10 (13.0)</td>
<td>146 (15.6)</td>
<td>0.648</td>
<td></td>
</tr>
<tr>
<td>Stage 2</td>
<td>315 (31.0) 28 (41.4)</td>
<td>28 (41.4)</td>
<td>28 (41.4)</td>
<td>0.532</td>
<td></td>
</tr>
<tr>
<td>Stage 3/4</td>
<td>102 (10.9) 4 (6.1)</td>
<td>98 (11.2)</td>
<td>98 (11.2)</td>
<td>0.532</td>
<td></td>
</tr>
<tr>
<td>Pericardial effusion</td>
<td>215 (21.1) 59 (7.3)</td>
<td>7 (12.1)</td>
<td>62 (7.1)</td>
<td>0.238</td>
<td></td>
</tr>
<tr>
<td>Conduction blocks</td>
<td>6 (0.6) 156 (15.4)</td>
<td>10 (13.0)</td>
<td>146 (15.6)</td>
<td>0.648</td>
<td></td>
</tr>
<tr>
<td>Muscle weakness</td>
<td>6 (0.6) 255 (25.1)</td>
<td>17 (21.1)</td>
<td>238 (25.4)</td>
<td>0.925</td>
<td></td>
</tr>
<tr>
<td><strong>Kidney</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal crisis history</td>
<td>4 (0.4) 30 (2.9)</td>
<td>2 (2.6)</td>
<td>28 (3.0)</td>
<td>1.000</td>
<td></td>
</tr>
<tr>
<td><strong>Laboratory parameters</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANA positive</td>
<td>16 (1.6) 961 (95.6)</td>
<td>75 (96.2)</td>
<td>886 (95.6)</td>
<td>1.000</td>
<td></td>
</tr>
<tr>
<td>ACA positive</td>
<td>64 (6.3) 88 (0.2)</td>
<td>6 (8.2)</td>
<td>82 (9.3)</td>
<td>0.929</td>
<td></td>
</tr>
<tr>
<td>Anti-Scl-70 positive</td>
<td>42 (4.1) 616 (62.9)</td>
<td>49 (62.6)</td>
<td>567 (62.7)</td>
<td>0.628</td>
<td></td>
</tr>
<tr>
<td>Anti-U1RNP positive</td>
<td>237 (23.2) 35 (4.5)</td>
<td>1 (1.6)</td>
<td>34 (4.7)</td>
<td>0.514</td>
<td></td>
</tr>
<tr>
<td>Anti-RNA polymerase III positive</td>
<td>453 (44.4) 58 (10.2)</td>
<td>5 (9.9)</td>
<td>53 (10.3)</td>
<td>1.000</td>
<td></td>
</tr>
<tr>
<td>Creatinine kinase elevation</td>
<td>75 (7.3) 100 (10.6)</td>
<td>8 (10.8)</td>
<td>92 (10.6)</td>
<td>1.000</td>
<td></td>
</tr>
<tr>
<td>Proxenuria</td>
<td>78 (7.6) 64 (6.8)</td>
<td>5 (6.9)</td>
<td>59 (6.8)</td>
<td>1.000</td>
<td></td>
</tr>
<tr>
<td>Hypocomplementaemia</td>
<td>192 (18.8) 58 (7.0)</td>
<td>3 (4.8)</td>
<td>55 (7.2)</td>
<td>0.613</td>
<td></td>
</tr>
<tr>
<td>ESR &lt;25 mm/h</td>
<td>117 (11.5) 371 (41.0)</td>
<td>24 (33.3)</td>
<td>347 (41.5)</td>
<td>0.382</td>
<td></td>
</tr>
<tr>
<td>CRP elevation</td>
<td>63 (6.2) 294 (30.7)</td>
<td>31 (41.9)</td>
<td>263 (29.8)</td>
<td>0.041</td>
<td></td>
</tr>
<tr>
<td>Active disease (VAI &gt;3)</td>
<td>154 (15.1) 340 (39.2)</td>
<td>20 (30.8)</td>
<td>320 (39.9)</td>
<td>0.187</td>
<td></td>
</tr>
<tr>
<td>Immunosuppressive therapy§</td>
<td>66 (6.5) 667 (69.8)</td>
<td>54 (73.0)</td>
<td>613 (69.6)</td>
<td>0.632</td>
<td></td>
</tr>
</tbody>
</table>

---

**Definitions of items and organ manifestation are according to EUSTAR.**

Data are presented as number (%) unless otherwise stated.

P values of univariate comparisons of baseline characteristics between skin progressors and non-progressors are shown (χ² tests or Fisher’s exact tests used for categorical variables and independent sample t-tests used for continuous variables, as appropriate).

*Disease duration was calculated as the difference between the date of the baseline visit and the date of the first non-Raynaud's symptom of the disease as reported by the patient.

†Pulmonary hypertension was globally judged on echocardiography by the treating physician.

‡Active disease was defined as a score >3 by calculating European Scleroderma Study Group disease activity indices for systemic sclerosis proposed by Valentini et al.45

§Immunosuppressive therapy was defined as treatment with corticosteroids (prednisone dose ≥2.5 mg/day or other dosage forms in equal dose) or any immunosuppressant.

ANA, antinuclear antibody; Anti-Scl-70, anti-topoisomerase 1 antibody; ACA, anti-centromere antibody; Anti-Scl-70, anti-topoisomerase 1 antibody; Creactive protein; CT, computed tomography; DLCO, diffusing capacity for carbon monoxide; ESR, erythrocyte sedimentation rate; FEV₁, forced expiratory volume in 1 sec; FVC, forced vital capacity; LVEF, left ventricular ejection fraction;mRSS, modified Rodnan skin score; NYHA, New York Heart Association; TLC, total lung capacity; VAI, Valentini activity index.
non-progressors (log-rank test \( p<0.001 \); figure 1A). In the subgroups of patients with low baseline mRSS and short disease duration, which reflect evidence-based recruitment parameters for recent clinical trials in skin fibrosis, skin progressors also had a significantly higher probability of FVC decline than non-progressors (baseline mRSS ≤22/51 units: 27/47 [57.4%] vs 202/596 [33.9%], \( p<0.001 \); disease duration ≤15 months: 7/12 [58.3%] vs 26/89 [29.2%], \( p=0.019 \), respectively) (figure 2A, C). There was no significant difference in the probability of FVC decline in the subgroups of patients with baseline mRSS >22/51 units and disease duration >15 months (figure 2B, D).

Overall, 320 of 781 patients (41.0%) met the FVC-DLCO composite definition of lung progression (relative decrease in FVC ≥10%, or 5%–9% combined with DLCO ≥15%) during a

Figure 1 Kaplan-Meier survival plots for (A) time to FVC decline ≥10%, (B) time to FVC-DLCO composite endpoint, (C) time to all-cause death and (D) time to overall disease progression during follow-up depending on the presence or absence of skin progression within 1 year. DLCO, diffusing capacity for carbon monoxide; FVC, forced vital capacity.

Figure 2 Kaplan-Meier survival plots for FVC decline ≥10% during follow-up depending on the presence or absence of skin progression within 1 year in subgroups of patients with (A) baseline mRSS ≤22/51 units, (B) baseline mRSS >22/51 units, (C) disease duration ≤15 months and (D) disease duration >15 months. FVC, forced vital capacity; mRSS, modified Rodnan skin score.
Systemic sclerosis

Figure 3 Kaplan-Meier survival plots for all-cause death during follow-up depending on the presence or absence of skin progression within 1 year in subgroups of patients with (A) baseline mRSS ≤22/51 units, (B) baseline mRSS >22/51 units, (C) disease duration ≤15 months and (D) disease duration >15 months. mRSS, modified Rodnan skin score.

Pulmonary hypertension

During a median follow-up of 3.8 years (IQR 1.9–5.8 years), 109 of 693 patients (15.7%) developed new PH. There were 5 (10.4%) and 104 (16.1%) events in the skin progressor and non-progressor groups, respectively, with no significant difference in probability of new PH between groups (log-rank test p=0.316; online supplementary figure S2C). When stratified by either baseline mRSS or disease duration, the only significant difference in probability of new PH between groups occurred in patients with disease duration >15 months, in whom skin progressors had a significantly lower probability of new PH compared with non-progressors (0/28 [0.0%] vs 89/528 [16.9%], respectively; p=0.026).

All-cause death

During a median follow-up of 3.4 years (IQR 1.8–5.9 years), 81 of 1021 patients (7.9%) died. There were 12 (15.4%) and 69 (7.3%) deaths in the skin progressor and non-progressor groups, respectively. The probability of all-cause death was significantly higher for skin progressors than non-progressors (log-rank test p=0.003; figure 1C). In the subgroups of patients with low baseline mRSS and short disease duration, skin progressors also had a significantly higher probability of all-cause death than non-progressors (baseline mRSS ≤22/51 units: 9/67 [13.4%] vs 54/752 [7.2%], p=0.017; disease duration ≤15 months: 4/19 [21.1%] vs 3/107 [2.8%], p=0.009, respectively) (figure 3A, C). In the subgroups of patients with baseline mRSS >22/51 units and
Systemic sclerosis

Figure 4 Kaplan-Meier survival plots for overall disease progression during follow-up depending on the presence or absence of skin progression within 1 year in subgroups of patients with (A) baseline mRSS ≤22/51 units, (B) baseline mRSS >22/51 units, (C) disease duration ≤15 months and (D) disease duration >15 months. mRSS, modified Rodnan skin score.

Overall disease progression
During a median follow-up of 4.6 years (IQR 2.2–6.6 years), 389 of 685 patients (56.8%) cumulatively had overall disease progression as defined above. There were 37 (74.0%) and 352 (55.4%) events in the skin progressor and non-progressor groups, respectively. The probability of overall disease progression was significantly higher for patients with skin progression than those without (log-rank test \( p=0.012 \); figure 1D). In the subgroups of patients with low baseline mRSS and short disease duration, skin progressors also had a significantly higher probability of overall disease progression than non-progressors (baseline mRSS ≤22/51 units: 33/45 [73.3%] vs 283/521 [54.3%], \( p=0.010 \); disease duration ≤15 months: 10/11 [90.9%] vs 31/71 [43.7%], \( p<0.001 \), respectively) (figure 4A, C). In the subgroups of patients with baseline mRSS >22/51 units and disease duration >15 months, no significant difference was observed in the probability of overall disease progression between groups (figure 4B, D).

Independent associations between skin progression and FVC decline and all-cause death
In the final multivariable Cox regression models, skin progression was independently associated with FVC decline ≥10% (HR 1.79; 95% CI 1.20 to 2.63; \( p=0.004 \)) and all-cause death (HR 2.58; 95% CI 1.31 to 5.09; \( p=0.006 \)). History of SRC, LVEF <45%, FVC <70%, DLCO <70% and age at baseline were also independently associated with all-cause death (table 2). Skin progression had a trend-towards association with overall disease progression (HR 1.40; 95% CI 0.98 to 1.99; \( p=0.063 \)) (online supplementary table S1).

DISCUSSION
We investigated the association between skin progression and subsequent visceral organ progression in the large, prospectively, multicentre, real-life EUSTAR cohort. Our findings indicate that patients with dcSSc and skin progression within 1 year have a higher probability of lung progression and worse survival during follow-up. These findings suggest that such patients should be monitored very carefully in clinical practice. The results also support the concept that inclusion of patients with lower mRSS or shorter disease duration can enrich clinical trials for progressive skin fibrosis, and this enrichment leads to study populations with more severe disease at higher risk of organ progression and overall death. Notably, this increased risk of more severe disease occurs at >1 year’s follow-up and will thus not be detectable in a classical 1-year randomised controlled trial. Our findings emphasise that mRSS progression within 1 year is an appropriate surrogate marker for more severe disease during follow-up.

This study also provides evidence for cohort enrichment in clinical studies aiming primarily at lung fibrosis. Several parameters, including dcSSc, anti-topoisomerase 1-positive status and decreased baseline FVC have been identified in multiple studies as predictors of lung progression in SSc.20–35 However, few studies have focused specifically on patients with dcSSc. In the current EUSTAR analysis, skin progression was associated with subsequent decline of lung function in patients with dcSSc, even after adjustment for potentially confounding predictors. We examined two definitions of lung progression based on pulmonary function tests. The conventional definition (relative decrease in FVC ≥10%), based on expert group consensus, has been widely used as an endpoint in previous clinical studies, while the exploratory FVC-DLCO composite definition has recently been shown to predict mortality in patients with SSc-related interstitial lung disease.35 Analyses with both definitions produced similar results, strengthening our findings.
Our findings are supported by the results of a study that focused on early dcSSc using a different definition of skin progression.23

One limitation of our analysis is the problem of missing values and loss to follow-up, which was inevitable in such a huge multicentre registry database. This partly explains the low number of patients during long-term follow-up. However, we tried to overcome this by multiple imputation before regression analysis and for most variables there were relatively few missing values. Second, we were unable to determine specific causes of death at all participating centres, and therefore only all-cause mortality, regardless of attribution to SSc, could be assessed. However, all-cause mortality is considered a more robust measure of disease outcome than SSc-associated mortality, as cause of death is often difficult to assign. Third, there was a relatively high proportion of new PH cases during follow-up in our cohort. This was the result of basing the definition on assessment of PH on echocardiography by the treating physician rather than on right heart catheterisation, which is required for formal diagnosis of PH. Unfortunately, right heart catheterisation data are not reliably available in the EUSTAR database, and echocardiography was the best available approximation of PH for the present analysis. Finally, as a result of the observational design, we did not evaluate the effect of treatment on outcomes. However, treatment of SSc, especially with immunosuppressive therapy, is always individualised and organ specific, and it is therefore difficult to accurately reflect the influence of treatment in an unselected heterogeneous cohort. In addition, there is a meaningful treatment-by-indication error in observational studies, making interpretation of results difficult. In our cohort, the proportions of patients receiving immunosuppressive treatment between groups at baseline were equal.

In conclusion, progressive skin fibrosis is associated with decline in lung function and worse survival in dcSSc during follow-up. The evidence-based findings obtained from the large prospective EUSTAR cohort allow optimisation of cohort enrichment in future clinical trials aimed at skin and lung fibrosis, and also help clinicians to identify patients at risk of lung progression in clinical practice.

### Author affiliations

1Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
2Graf Biostatistics, Winterthur, Switzerland
3Clinical Development Pulmonology, Bayer US LLC, Whippany, New Jersey, USA
4Data Science and Analytics, Bayer plc, Reading, UK
5Rheumatology A Department, Paris Descartes University, INSERM U1016, Sorbonne, Paris Cité, Cochin Hospital, Paris, France
6Division of Rheumatology, University of Florence, Florence, Italy
7Department of Medicine, Division of Rheumatology, University of Western Ontario, St. Joseph’s Health Care, London, Western Ontario, Canada
8Department of Rheumatology, Royal Free Hospital, University College London, London, UK
9Scleroderma Program, Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA

### Acknowledgements

The authors thank Nicole Schneider for excellent administration and data entry into the EUSTAR cohort. Medical writing assistance was provided by Adelphi Communications Ltd (Bollington, UK), funded by Bayer AG (Berlin, Germany).

### Collaborators

EUSTAR Collaborators (numerical order of centres): Marco Matucci-Cerinic, Serena Guiducci, University of Florence, Italy; Ulrich Walker, Veronika Jaeger, Bettina Bannert, University Hospital Basel, Switzerland; Giovanni Lapadula, School of Medicine University of Bari, Italy; Radim Becvarova, 1st Medical School, Charles University, Prague, Czech Republic; Maurizio Cutolo, University of Genova, Italy; Gabriele Valenti, Policlinico U.O. Reumatologia, Naples, Italy; Elise Siegert, Charité University Hospital Berlin, Berlin, Germany; Simona Rednic, University of Medicine & Pharmacy, ‘Iuliu Hatieganu’ Cluj, Cluj-Napoca, Romania; Yannick Allanore, University Cochin Hospital, Paris, France; C Montecucco, IRCs Policlinico S Matteo, Pavia, Italy; Patrizia E Carella, Hospital 12 de Octubre, Madrid, Spain; Srdan Novak, KBC Rijeka, Croatia; László Czirják, Cecilia Varja, University of Pécs.
Systemic sclerosis

Hungary; Carlo Chizzolini, Daniela Allai, University Hospital Geneva, Switzerland; Eugene J Kucharz, Medical University of Silesia, Katowice, Poland; Franco Cozzi, University of Padova, Italy; Blaz Rozman, University Medical Center Ljubljana, Slovenia; Carmel Mallia, ‘Sella Maris’, Balzan, Malta; Armando Gabrielli, Istituto di Clinica Medica Generale, Ematologia ed Immunologia Clinica, Università Politecnica delle Marche, Polonia; Paolo Carnaghi, Università degli Studi di Verona, Italy; Carol Black, Royal Free and University College School of Medicine, London, UK; Nemania Damjanov, Institute of Rheumatology Belgrade, Serbia and Montenegro; Jörg Henes, Medizinische Universitätsklinik Abt. II, Tübingen, Germany; Vera Ortiz Santamaría, Rheumatology Granollers General Hospital, Barcelona, Spain; Stefan Heilmann, Marienhospital Stuttgart, Germany; Matthias Seidel, Medizinische Universität-Poliklinik, Bonn, Germany; Jose Antonio Perea, Universidad, Coimbra, Portugal; Bojana Stamenkovic, Institute for Prevention, Treatment and Rehabilitation Rheumatic and Cardiovascular Disease Niška Banja, Serbia and Montenegro; Carlo Francesco Selmi, University of Milan, Italy; Mohammed T Khuly, Chris Han Baragarawan Hospital and University of the Witwatersrand, Johannesburg, South Africa; LeN Dinenso, VA hasonova Center for Rheumatology and Immunology, Olomouc, Czech Republic; Ulf Kockhoff, Freiburg, Germany; Akka Naueh, Germany; Merete Engelhart, University Hospital of Gentofte, Hellerup, Denmark; Eric Hachulla, Hôpital Claude Huriez, Lille, France; Valeria Riccieri, ‘Sapienza’ Università di Roma, Italy; Ruxandra Maria Raptinis, University Hospital of Strasbourg, France; commercials.

Funding This study was supported by a grant from Bayer AG.

Disclaimer Bayer did not have any influence on the interpretation of the data.

Competing interests OD has obtained research support from Bayer, Sanofi, Enbrel, Boehringer Ingelheim, Acteon and Pfizer. He is a scientific consultant for 4D Science, Acteon, Active Biotec, Bayer, Biogenidec, BMS, Boehringer Ingelheim, ChemoAb, Epipharm, Enbrel, epoxe foundation, Genentech/Reche, GSK, Inventiva, Llidy, Medac, Immunem, Pharmacists, Pfizer, Serodaphm and Sinoxoa, and has a patent licensed on mir-29 for the treatment of systemic sclerosis. DK has consultancy relationships and/or has received grant/research support from Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Genentech/Reche, NH, Pfizer, Sanofi-Aventis Pharmaceuticals, Acteon Pharmaceuticals US, Chemomab, Corbus, Covis, Cytori, Eics, EMD Serono, Gilead, GlaxoSmithKline and UCB Pharma. He is a shareholder of Eics. CPD has consultancy relationships with and/or has received speakers’ bureau fees from Acteon Pharmaceuticals US, Bayer AG, GlaxoSmithKline, CSL, sanofi-aventis, Merck-Spon, Pfizer, sanofi-aventis, sanofi-aventis, sanofi-Aventis Pharmaceuticals and Boehringer Ingelheim. JdOP has consultancy relationships and/or has received consultant’s and/or has received grant/research support from Acteon, Bayer AG, Bristol-Myers Squibb, Merck, Pfizer Inc and Roche. MM-C has consultancy relationships and/or has received grant/research support from Acteon, Bayer-Myers Squibb, Acteon, UCB Pharma, Bayer, Chemomab, Genentech/Reche, and Inventiva and Llidy. VA has consultancy relationships with and/or has received grant/ research support from Acteon, Pharmaceuticals US, Bayer AG, Bristol-Myers Squibb, Inventiva, Medac, Pfizer Inc, Roche Pharmaceuticales, Genentech and Biogen-IDEC Inc., Sanofi-Aventis Pharmaceuticals and Servier. JdOP and JC are employees of Bayer. WW, SJ and NG have nothing to disclose.

Ethics approval All contributing EUSTAR centres have obtained approval from their respective local ethics committee for including patients’ data in the EUSTAR database and written informed consent was obtained in those centres, where required by the ethics committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES


Systemic sclerosis


Progressive skin fibrosis is associated with decline in lung function and worse survival in people with dcSSc

Worsening skin disease could be used as a marker of internal organ damage in people with diffuse cutaneous subtype of systemic sclerosis (dcSSc)

INTRODUCTION
Systemic sclerosis is a rare but serious disease of the connective tissues, characterised by thickening of skin and by triggering the immune system to attack itself (autoimmunity). This can cause hardening (fibrosis) and swelling of the skin and damage of different organs such as lungs, heart, kidneys and gastrointestinal problems. It is more common in women than in men.

The diffuse cutaneous subtype of systemic sclerosis (often shortened to dcSSc) affects around 30% of people with systemic sclerosis. It is linked with early damage to a person’s internal organs including the lungs and kidneys, as well as painful skin thickening that quickly gets worse.

WHAT DID THE AUTHORS HOPE TO FIND?
The authors wanted to find out whether progressive skin fibrosis, measured by the modified Rodnan skin score (mRSS) is linked to worsening of organ damage and death in people with dcSSc.

WHO WAS STUDIED?
The study looked at just over 1000 people with dcSSc. Everyone included in the study visited their doctor at least once a year, and had a measured mRSS score of 7 or more at the first visit, as well as repeated mRSS 9–15 months later.

HOW WAS THE STUDY CONDUCTED?
This was an observational study from the prospective EUSTAR (European Scleroderma Trials and Research group) database. The EUSTAR database is a multi-centre online database that follows more than 16,000 people with systemic sclerosis in more than 200 international centres (www.eustar.org). This means that the authors analysed the existing database, with yearly collected, predefined data assessments from people in a real-life clinical situation. There was no interventional treatment given as part of this study.

The authors analysed the EUSTAR database to find the records of people with dcSSc whose mRSS score had worsened over 9–15 months, suggesting that they had progression of skin fibrosis. They then looked to see if there was a link between the mRSS measurement and progression of disease in people’s organs, including their lung function and causes of death.

WHAT WERE THE MAIN FINDINGS OF THE STUDY?
The study found that worsening skin fibrosis over a period of 1 year was associated with a decline in lung function and worse survival in people with dcSSc at long-term follow up. The results suggest that the mRSS measurement can be used as a marker in people with dcSSc to identify those at risk of organ damage or death at later disease stages. These results will be helpful in choosing SSc patients for future trials of hopefully more effective new therapies, as well as in working out who is at most risk.

ARE THESE FINDINGS NEW?
Yes. This is the first time that this link has been investigated.
WHAT ARE THE LIMITATIONS OF THE STUDY?
There are some weaknesses of observational studies. Firstly, the outcome for each person cannot be disentangled from their baseline characteristics or the treatment that they received. Additionally, there can be information missing from patient records, because it was not collected or recorded properly, or because people did not return to the clinic for assessment. In this study, for those people who died, it was not always clear what the cause of death had been. However, the authors are confident that the way they did their statistical analysis means that this is not a problem for the overall results.

WHAT DO THE AUTHORS PLAN ON DOING WITH THIS INFORMATION?
The authors expect that this information will be used to design future clinical trials in people with dcSSc, using mRSS as an outcome measure, for example as part of a combined measure, to develop better therapies.

WHAT DOES THIS MEAN FOR ME?
If you have rapidly progressive dcSSc, there are limited treatment options at the moment. Better treatments are needed for people with this disease, but it is hoped that in the future there will be more options. If you have skin fibrosis that gets worse over a short period of time, your doctor should monitor you for progression in your organs – especially your lungs.

If you have concerns about your disease or the medicine you are taking, you should talk to your doctor.

Disclaimer: This is a summary of a scientific article written by a medical professional (“the Original Article”). The Summary is written to assist non medically trained readers to understand general points of the Original Article. It is supplied “as is” without any warranty. You should note that the Original Article (and Summary) may not be fully relevant nor accurate as medical science is constantly changing and errors can occur. It is therefore very important that readers not rely on the content in the Summary and consult their medical professionals for all aspects of their health care and only rely on the Summary if directed to do so by their medical professional. Please view our full Website Terms and Conditions. http://www.bmj.com/company/legal-information/

Date prepared: May 2019

Summary based on research article published on: 9 March 2019


Copyright © 2019 BMJ Publishing Group Ltd & European League Against Rheumatism. Medical professionals may print copies for their and their patients and students non commercial use. Other individuals may print a single copy for their personal, non commercial use. For other uses please contact our Rights and Licensing Team.